Tonstad S, Gørbitz C, Ose L, Malt U F
Medisinsk avdeling A, Rikshospitalet, Oslo.
Tidsskr Nor Laegeforen. 1994 Aug 20;114(19):2262-4.
The efficacy and safety of treatment with recommended doses of lovastatin (20, 40 and 80 mg/day) and pravastatin (10, 20 and 40 mg/day) were compared in 48 men and women with primary hyperlipidemia and LDL-cholesterol > or = 4.1 mmol/l following dietary intervention. Each dose was taken for six weeks in this double-blind, parallel, randomized study. Lovastatin was found to reduce LDL-cholesterol by 22-37% and pravastatin by 18-26%. HDL-cholesterol levels increased and triglyceride levels decreased to the same extent in both groups. The number of patients who reported adverse events in the course of the study was small. No clinically significant changes occurred in laboratory tests, nor in sleep scores obtained from a standardized questionnaire. Neither drug had any effect on the responses to a quality of life screening questionnaire, nor were any significant changes in depressive symptoms seen during the 18 weeks of treatment.
在48名经饮食干预后患有原发性高脂血症且低密度脂蛋白胆固醇≥4.1 mmol/l的男性和女性中，比较了推荐剂量的洛伐他汀（20、40和80毫克/天）和普伐他汀（10、20和40毫克/天）治疗的疗效和安全性。在这项双盲、平行、随机研究中，每种剂量服用六周。发现洛伐他汀可使低密度脂蛋白胆固醇降低22% - 37%，普伐他汀可使低密度脂蛋白胆固醇降低18% - 26%。两组高密度脂蛋白胆固醇水平均升高，甘油三酯水平均下降至相同程度。在研究过程中报告不良事件的患者数量较少。实验室检查以及从标准化问卷中获得的睡眠评分均未出现具有临床意义的变化。两种药物对生活质量筛查问卷的回答均无影响，在18周的治疗期间抑郁症状也未出现任何显著变化。
